FindTrial
Sign In

A Case of RET Inhibitor in the Treatment of Leptomeningeal Metastasis from Advanced Lung Adenocarcinoma

A Case of RET Inhibitor in the Treatment of Leptomeningeal Metastasis from Advanced Lung Adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111263
Enrollment
Unknown
Registered
2025-10-28
Start date
2025-11-15
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Adenocarcinoma

Interventions

Treatment group:None

Sponsors

Tongde Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Between April 2022 and September 2025, there was 1 patient who was hospitalized in the oncology department and received treatment with a RET inhibitor for leptomeningeal metastases from advanced lung adenocarcinoma.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
CEA;—

Secondary

MeasureTime frame
Creatine Phosphokinase;Creatine Kinase-MB;High-sensitivity Cardiac Troponin I;—

Countries

China

Contacts

Public ContactZhang Qiqing

Tongde Hospital of Zhejiang Province

zhangqiqingelva@163.com+86 571 89972479

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026